Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test

References

• Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D E, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Schneider P M, Hung M C, Chiocca S M, Manning J, Zhao X Y, Fang K, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 1989; 4: 4968–4971
   Google Scholar
• Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 57: 285–290
   PubMedGoogle Scholar
• Slichenmyer W, Fry D. Anticancer therapy targeting the Erb B family of receptor tyrosine kinases. Semin Oncol 2001; 28: 67–79
   PubMed Web of Science ®Google Scholar
• Thor A D, Berry D A, Budman D R, Muss H B, Kute T, Henderson I C, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast. J Natl Cancer Inst 1998; 90: 1346–1360
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. Optimal duration therapy with trastuzumab. Semin Oncol 2001; 28(Suppl 18)1–2
   PubMed Web of Science ®Google Scholar
• Romond E H, Perez E A, Bryant J, Suman V J, Geyer C E, Jr, Davidson N E, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684
   PubMed Web of Science ®Google Scholar
• Fisher S G, Fisher R I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 6524–6534
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist 2004; 9: 417–421
   PubMed Web of Science ®Google Scholar
• Rastetter W, Molina A, White C. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annual Rev Med 2004; 55: 477–503
   PubMed Web of Science ®Google Scholar
• Bairey O, Pazgal I, Okon E, Shaklai M, Morgenshtern S. Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphoma, an immunohistochemical study. Arch Pathol Lab Med 2002; 126: 574–576
   PubMed Web of Science ®Google Scholar
• Luftner D, Genvresse I, Geppert R, Kaufmann O, Dietel M, Possinger K. Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma. Anticancer Res 2004; 24: 3233–3237
   PubMed Web of Science ®Google Scholar
• Muller M, Grunebach F, Kayser K, Vogel W, Nencioni A, Brugger W, et al. Expression of Her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res 2003; 9: 3448–3453
   PubMed Web of Science ®Google Scholar
• Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pinyol M, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004; 22: 3498–3506
   PubMed Web of Science ®Google Scholar
• Harris L, Liotcheva V, Broadwater G, Ramirez M, Maimonis P, Anderson S. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19: 1698–1706
   PubMed Web of Science ®Google Scholar
• Gupta D, Middleton L P, Whitaker M J, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Pathol 2003; 119: 381–387
   Web of Science ®Google Scholar
• Kumamoto H, Sasano H, Taniguchi T, Suzki T, Moriya T, Ichinohasama R. Chromatic in situ hybridization analysis of Her-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin®) therapy. Pathology Int 2001; 51: 579
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69–86
   PubMedGoogle Scholar
• Coussens L, Yang-Feng T L, Liao Y C, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–1139
   PubMed Web of Science ®Google Scholar
• Carraway K L, Cantly L A. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5–8
   PubMed Web of Science ®Google Scholar
• Wen D, Peles E, Cupples R, Suggs S V, Bacus S S, Luo Y, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992; 69: 559–572
   PubMed Web of Science ®Google Scholar
• Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target of therapy. Stem Cells 1998; 16: 413–428
   PubMed Web of Science ®Google Scholar
• Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552–556
   PubMed Web of Science ®Google Scholar
• Thomas D G, Giordano T J, Sanders D, Biermann S, Sondak V K, Trent J C, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103: 830–838
   PubMed Web of Science ®Google Scholar
• Stein H. Diagnosis of Hodgkin's disease, Hodgkin's like anaplastic large cell lymphoma, and T cell/histiocyte-rich B cell lymphoma. Human lymphoma: clinical implications of the REAL classification, Vol. 52, D Y Mason, N L Harris. Springer, London, England 1999; 1–4
   Google Scholar
• Sgrignoli A, Abati A. Cytologic diagnosis of anaplastic large cell lymphoma. Acta Cytol 1997; 41: 1048–1052
   PubMed Web of Science ®Google Scholar
• Gupta D, Middleton L, Whitaker M, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119: 381–387
   PubMed Web of Science ®Google Scholar